Residual ASCVD risk may be present even after the optimization of LDL-C levels and increasing evidence has suggested that elevated Lp(a) is an emerging CVD risk factor that has been shown to be a causal CVD risk factor in epidemiological and genetic studies, as well as enhance CVD risk prediction in certain patients. As emerging CVD risk factors, including Lp(a), are increasingly recognized as a target for therapy in the prevention and treatment of ASCVD, clinicians should be aware of the therapeutic advances in this field. In this activity, experts evaluate the effectiveness and safety of these new approaches, along with current Lp(a) management strategies and patient care practices. The content is structured into an interactive, online compendium divided into chapters, making it easy to digest. Additionally, the compendium is enriched with supplementary resources and recommended readings for further exploration.
- Provider:Partners for Advancing Clinical Education (PACE)
- Activity Link: https://cme.tarsusmedicaleducation.com/cardiometabolic-health-congress-cmhc-/content/understanding-role-lpa-cv-risk-marker-therapeutic-target-prevention-ascvd_1684#group-tabs-node-course-default1
- Start Date: 2024-06-12 05:00:00
- End Date: 2024-06-12 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.5 hours
Dietetic CPEUs: 1.5 hours
Nursing: 1.5 hours
Pharmacy: 1.5 hours - Commercial Support: Source: Novartis Corporation Pharmaceuticals - Amount: 66250.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all